Surmounting Cancer Drug Resistance: New Perspective on RNA-Binding Proteins

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2023 Aug 26

PMID 37631029

Authors

Yiyuan Feng

Sha Zhu

Tengwen Liu

Guoguo Zhi

Bingjie Shao

Jibin Liu

Baixue Li

Cen Jiang

Quansheng Feng

Peijie Wu

Dong Wang

Affiliations

Soon will be listed here.

Abstract

RNA-binding proteins (RBPs), being pivotal elements in both physiological and pathological processes, possess the ability to directly impact RNA, thereby exerting a profound influence on cellular life. Furthermore, the dysregulation of RBPs not only induces alterations in the expression levels of genes associated with cancer but also impairs the occurrence of post-transcriptional regulatory mechanisms. Consequently, these circumstances can give rise to aberrations in cellular processes, ultimately resulting in alterations within the proteome. An aberrant proteome can disrupt the equilibrium between oncogenes and tumor suppressor genes, promoting cancer progression. Given their significant role in modulating gene expression and post-transcriptional regulation, directing therapeutic interventions towards RBPs represents a viable strategy for combating drug resistance in cancer treatment. RBPs possess significant potential as diagnostic and prognostic markers for diverse cancer types. Gaining comprehensive insights into the structure and functionality of RBPs, along with delving deeper into the molecular mechanisms underlying RBPs in tumor drug resistance, can enhance cancer treatment strategies and augment the prognostic outcomes for individuals afflicted with cancer.

Citing Articles

Navigating a complex dance: the interplay between RNA-binding proteins and T cells in oral epithelial plasticity.

Vijayakumar A, Vasudevan S, John S, Ozbun M, Bartee E, Palanisamy V Immunometabolism (Cobham). 2025; 7(1):e00054.

PMID: 39816132 PMC: 11731067. DOI: 10.1097/IN9.0000000000000054.

Insights into the Mode and Mechanism of Interactions Between RNA and RNA-Binding Proteins.

Fang Y, Liu X, Liu Y, Xu N Int J Mol Sci. 2024; 25(21).

PMID: 39518890 PMC: 11545484. DOI: 10.3390/ijms252111337.

References

Hamdollah Zadeh M, Amin E, Hoareau-Aveilla C, Domingo E, Symonds K, Ye X . Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance. Mol Oncol. 2014; 9(1):167-78. PMC: 4286123. DOI: 10.1016/j.molonc.2014.07.017. View

Sahu A, Singhal U, Chinnaiyan A . Long noncoding RNAs in cancer: from function to translation. Trends Cancer. 2015; 1(2):93-109. PMC: 4672369. DOI: 10.1016/j.trecan.2015.08.010. View

Jonas K, Calin G, Pichler M . RNA-Binding Proteins as Important Regulators of Long Non-Coding RNAs in Cancer. Int J Mol Sci. 2020; 21(8). PMC: 7215867. DOI: 10.3390/ijms21082969. View

Danan-Gotthold M, Golan-Gerstl R, Eisenberg E, Meir K, Karni R, Levanon E . Identification of recurrent regulated alternative splicing events across human solid tumors. Nucleic Acids Res. 2015; 43(10):5130-44. PMC: 4446417. DOI: 10.1093/nar/gkv210. View

Masamha C, Xia Z, Yang J, Albrecht T, Li M, Shyu A . CFIm25 links alternative polyadenylation to glioblastoma tumour suppression. Nature. 2014; 510(7505):412-6. PMC: 4128630. DOI: 10.1038/nature13261. View

Vikesaa J, Hansen T, Jonson L, Borup R, Wewer U, Christiansen J . RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 2006; 25(7):1456-68. PMC: 1440323. DOI: 10.1038/sj.emboj.7601039. View

Hitti E, Bakheet T, Al-Souhibani N, Moghrabi W, Al-Yahya S, Al-Ghamdi M . Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins. Cancer Res. 2016; 76(14):4068-80. DOI: 10.1158/0008-5472.CAN-15-3110. View

Lal A, Mazan-Mamczarz K, Kawai T, Yang X, Martindale J, Gorospe M . Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J. 2004; 23(15):3092-102. PMC: 514922. DOI: 10.1038/sj.emboj.7600305. View

Graff J, Konicek B, Lynch R, Dumstorf C, Dowless M, McNulty A . eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res. 2009; 69(9):3866-73. DOI: 10.1158/0008-5472.CAN-08-3472. View

10.

Wu J, Lin Y, Tseng C, Chen H, Wang L . Crabp2 Promotes Metastasis of Lung Cancer Cells via HuR and Integrin β1/FAK/ERK Signaling. Sci Rep. 2019; 9(1):845. PMC: 6351595. DOI: 10.1038/s41598-018-37443-4. View

11.

Jimenez M, Arechederra M, Avila M, Berasain C . Splicing alterations contributing to cancer hallmarks in the liver: central role of dedifferentiation and genome instability. Transl Gastroenterol Hepatol. 2018; 3:84. PMC: 6232053. DOI: 10.21037/tgh.2018.10.11. View

12.

Gu W, Pan F, Singer R . Blocking beta-catenin binding to the ZBP1 promoter represses ZBP1 expression, leading to increased proliferation and migration of metastatic breast-cancer cells. J Cell Sci. 2009; 122(Pt 11):1895-905. PMC: 2684840. DOI: 10.1242/jcs.045278. View

13.

Grishin N . KH domain: one motif, two folds. Nucleic Acids Res. 2001; 29(3):638-43. PMC: 30387. DOI: 10.1093/nar/29.3.638. View

14.

Moran-Jones K, Grindlay J, Jones M, Smith R, Norman J . hnRNP A2 regulates alternative mRNA splicing of TP53INP2 to control invasive cell migration. Cancer Res. 2009; 69(24):9219-27. PMC: 6485436. DOI: 10.1158/0008-5472.CAN-09-1852. View

15.

Muralidharan R, Babu A, Amreddy N, Srivastava A, Chen A, Zhao Y . Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth and By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther. 2017; 16(8):1470-1486. PMC: 5544587. DOI: 10.1158/1535-7163.MCT-17-0134. View

16.

Stoecklin G, Anderson P . Posttranscriptional mechanisms regulating the inflammatory response. Adv Immunol. 2006; 89:1-37. DOI: 10.1016/S0065-2776(05)89001-7. View

17.

Zhu H, Berkova Z, Mathur R, Sehgal L, Khashab T, Tao R . HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer. Mol Cancer Res. 2015; 13(5):809-18. DOI: 10.1158/1541-7786.MCR-14-0241. View

18.

Bono F, Ebert J, Unterholzner L, Guttler T, Izaurralde E, Conti E . Molecular insights into the interaction of PYM with the Mago-Y14 core of the exon junction complex. EMBO Rep. 2004; 5(3):304-10. PMC: 1299003. DOI: 10.1038/sj.embor.7400091. View

19.

Matia-Gonzalez A, Laing E, Gerber A . Conserved mRNA-binding proteomes in eukaryotic organisms. Nat Struct Mol Biol. 2015; 22(12):1027-33. PMC: 5759928. DOI: 10.1038/nsmb.3128. View

20.

Konicek B, Stephens J, McNulty A, Robichaud N, Peery R, Dumstorf C . Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res. 2011; 71(5):1849-57. DOI: 10.1158/0008-5472.CAN-10-3298. View